NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Core Insights - NeuroSense Therapeutics has been granted U.S. Patent No. 12,527,768 for the use of PrimeC combination in treating Alzheimer's disease, extending patent protection through 2043, which strengthens the company's intellectual property position [1][8] - The company recently completed a proof-of-concept study for Alzheimer's disease, with top-line results indicating a favorable safety and tolerability profile, with further clinical and biomarker outcomes expected in Q1 2026 [2][8] Company Overview - NeuroSense Therapeutics is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease, addressing significant unmet medical needs [5] - The company's lead drug candidate, PrimeC, is an extended-release oral formulation combining ciprofloxacin and celecoxib, designed to target multiple mechanisms of neurodegeneration and inflammation [4][5] Alzheimer's Disease Context - Alzheimer's disease is a leading cause of dementia, affecting over 30 million people globally, characterized by memory loss and cognitive decline, with no current cure available [3] - There is a significant unmet need for disease-modifying treatments that can slow or halt the progression of Alzheimer's disease, making approaches like PrimeC potentially impactful [3]